Ultromics designed EchoGo Amyloidosis to evaluate routine echocardiogram results for signs of cardiac amyloidosis. It received the FDA's breakthrough device designation back in 2023.

The software is the first of its kind to achieve the FDA's approval for detecting, measuring and grading ARIA on MRI scans—a task that is critical in managing the disease. 

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

The new code family was created to "capture the physician work involving patients with implanted medical devices that require access to MR diagnostic procedures."

Authorities became suspicious of the doctor after intercepting a package containing around 15 pounds of gamma-butyrolactone, a common date rape drug also known as “liquid ecstasy."